{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:54:03Z","timestamp":1790880843665,"version":"4.1.0"},"reference-count":54,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica\u2014Fondo para la investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","award":["FONCyT-program"],"award-info":[{"award-number":["FONCyT-program"]}]},{"name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica\u2014Fondo para la investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","award":["PICT 2017-3005"],"award-info":[{"award-number":["PICT 2017-3005"]}]},{"name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica\u2014Fondo para la investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","award":["2020-1782"],"award-info":[{"award-number":["2020-1782"]}]},{"name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica\u2014Fondo para la investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","award":["SECyT-UNC, Consolidar 1, 2018-2022, N\u00b0: 32720220400365CB"],"award-info":[{"award-number":["SECyT-UNC, Consolidar 1, 2018-2022, N\u00b0: 32720220400365CB"]}]},{"name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica\u2014Fondo para la investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","award":["N\u00b0 101007804 (Micro4Nano)"],"award-info":[{"award-number":["N\u00b0 101007804 (Micro4Nano)"]}]},{"DOI":"10.13039\/100010442","name":"Secretar\u00eda de Ciencia y Tecnolog\u00eda, Universidad Nacional de C\u00f3rdoba","doi-asserted-by":"publisher","award":["FONCyT-program"],"award-info":[{"award-number":["FONCyT-program"]}],"id":[{"id":"10.13039\/100010442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010442","name":"Secretar\u00eda de Ciencia y Tecnolog\u00eda, Universidad Nacional de C\u00f3rdoba","doi-asserted-by":"publisher","award":["PICT 2017-3005"],"award-info":[{"award-number":["PICT 2017-3005"]}],"id":[{"id":"10.13039\/100010442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010442","name":"Secretar\u00eda de Ciencia y Tecnolog\u00eda, Universidad Nacional de C\u00f3rdoba","doi-asserted-by":"publisher","award":["2020-1782"],"award-info":[{"award-number":["2020-1782"]}],"id":[{"id":"10.13039\/100010442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010442","name":"Secretar\u00eda de Ciencia y Tecnolog\u00eda, Universidad Nacional de C\u00f3rdoba","doi-asserted-by":"publisher","award":["SECyT-UNC, Consolidar 1, 2018-2022, N\u00b0: 32720220400365CB"],"award-info":[{"award-number":["SECyT-UNC, Consolidar 1, 2018-2022, N\u00b0: 32720220400365CB"]}],"id":[{"id":"10.13039\/100010442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010442","name":"Secretar\u00eda de Ciencia y Tecnolog\u00eda, Universidad Nacional de C\u00f3rdoba","doi-asserted-by":"publisher","award":["N\u00b0 101007804 (Micro4Nano)"],"award-info":[{"award-number":["N\u00b0 101007804 (Micro4Nano)"]}],"id":[{"id":"10.13039\/100010442","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program under the RISE Marie Sk\u0142odowska-Curie","award":["FONCyT-program"],"award-info":[{"award-number":["FONCyT-program"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program under the RISE Marie Sk\u0142odowska-Curie","award":["PICT 2017-3005"],"award-info":[{"award-number":["PICT 2017-3005"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program under the RISE Marie Sk\u0142odowska-Curie","award":["2020-1782"],"award-info":[{"award-number":["2020-1782"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program under the RISE Marie Sk\u0142odowska-Curie","award":["SECyT-UNC, Consolidar 1, 2018-2022, N\u00b0: 32720220400365CB"],"award-info":[{"award-number":["SECyT-UNC, Consolidar 1, 2018-2022, N\u00b0: 32720220400365CB"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program under the RISE Marie Sk\u0142odowska-Curie","award":["N\u00b0 101007804 (Micro4Nano)"],"award-info":[{"award-number":["N\u00b0 101007804 (Micro4Nano)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Polyelectrolyte\u2013drug complexes are interesting alternatives to improve unfavorable drug properties. Vancomycin (VAN) is an antimicrobial used in the treatment of methicillin-resistant Staphylococcus aureus pulmonary infections in patients with cystic fibrosis. It is generally administered intravenously with a high incidence of adverse side effects, which could be reduced by intrapulmonary administration. Currently, there are no commercially available inhalable formulations containing VAN. Thus, the present work focuses on the preparation and characterization of an ionic complex between hyaluronic acid (HA) and VAN with potential use in inhalable formulations. A particulate\u2013solid HA-VAN25 complex was obtained by spray drying from an aqueous dispersion. FTIR spectroscopy and thermal analysis confirmed the ionic interaction between HA and VAN, while an amorphous diffraction pattern was observed by X-ray. The powder density, geometric size and morphology showed the suitable aerosolization and aerodynamic performance of the powder, indicating its capability of reaching the deep lung. An in vitro extended-release profile of VAN from the complex was obtained, exceeding 24 h. Microbiological assays against methicillin-resistant and -sensitive reference strains of Staphylococcus aureus showed that VAN preserves its antibacterial efficacy. In conclusion, HA-VAN25 exhibited interesting properties for the development of inhalable formulations with potential efficacy and safety advantages over conventional treatment.<\/jats:p>","DOI":"10.3390\/pharmaceutics16040436","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T05:10:53Z","timestamp":1711084253000},"page":"436","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Novel Dry Hyaluronic Acid\u2013Vancomycin Complex Powder for Inhalation, Useful in Pulmonary Infections Associated with Cystic Fibrosis"],"prefix":"10.3390","volume":"16","author":[{"given":"Mar\u00eda S.","family":"Magi","sequence":"first","affiliation":[{"name":"Departamento de Ciencias Farmac\u00e9uticas, Facultad de Ciencias Qu\u00edmicas, Universidad Nacional de C\u00f3rdoba (UNC), C\u00f3rdoba X5000GYA, Argentina"},{"name":"Unidad de Investigaci\u00f3n y Desarrollo en Tecnolog\u00eda Farmac\u00e9utica (UNITEFA), Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET-UNC), Haya de la Torre y Medina Allende, Ciudad Universitaria, C\u00f3rdoba X5000HUA, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanina","family":"de Lafuente","sequence":"additional","affiliation":[{"name":"Departamento de Ciencias Farmac\u00e9uticas, Facultad de Ciencias Qu\u00edmicas, Universidad Nacional de C\u00f3rdoba (UNC), C\u00f3rdoba X5000GYA, Argentina"},{"name":"Unidad de Investigaci\u00f3n y Desarrollo en Tecnolog\u00eda Farmac\u00e9utica (UNITEFA), Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET-UNC), Haya de la Torre y Medina Allende, Ciudad Universitaria, C\u00f3rdoba X5000HUA, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0215-2350","authenticated-orcid":false,"given":"Eride","family":"Quarta","sequence":"additional","affiliation":[{"name":"Food and Drug Department, University of Parma, Parco Area delle Scienze 27\/A, 43124 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda C.","family":"Palena","sequence":"additional","affiliation":[{"name":"Departamento de Ciencias Farmac\u00e9uticas, Facultad de Ciencias Qu\u00edmicas, Universidad Nacional de C\u00f3rdoba (UNC), C\u00f3rdoba X5000GYA, Argentina"},{"name":"Unidad de Investigaci\u00f3n y Desarrollo en Tecnolog\u00eda Farmac\u00e9utica (UNITEFA), Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET-UNC), Haya de la Torre y Medina Allende, Ciudad Universitaria, C\u00f3rdoba X5000HUA, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla del R.","family":"Ardiles","sequence":"additional","affiliation":[{"name":"Departamento de Ciencias Farmac\u00e9uticas, Facultad de Ciencias Qu\u00edmicas, Universidad Nacional de C\u00f3rdoba (UNC), C\u00f3rdoba X5000GYA, Argentina"},{"name":"Unidad de Investigaci\u00f3n y Desarrollo en Tecnolog\u00eda Farmac\u00e9utica (UNITEFA), Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET-UNC), Haya de la Torre y Medina Allende, Ciudad Universitaria, C\u00f3rdoba X5000HUA, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4836-4842","authenticated-orcid":false,"given":"Paulina L.","family":"P\u00e1ez","sequence":"additional","affiliation":[{"name":"Departamento de Ciencias Farmac\u00e9uticas, Facultad de Ciencias Qu\u00edmicas, Universidad Nacional de C\u00f3rdoba (UNC), C\u00f3rdoba X5000GYA, Argentina"},{"name":"Unidad de Investigaci\u00f3n y Desarrollo en Tecnolog\u00eda Farmac\u00e9utica (UNITEFA), Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET-UNC), Haya de la Torre y Medina Allende, Ciudad Universitaria, C\u00f3rdoba X5000HUA, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-1456","authenticated-orcid":false,"given":"Fabio","family":"Sonvico","sequence":"additional","affiliation":[{"name":"Food and Drug Department, University of Parma, Parco Area delle Scienze 27\/A, 43124 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4472-4823","authenticated-orcid":false,"given":"Francesca","family":"Buttini","sequence":"additional","affiliation":[{"name":"Food and Drug Department, University of Parma, Parco Area delle Scienze 27\/A, 43124 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro F.","family":"Jimenez-Kairuz","sequence":"additional","affiliation":[{"name":"Departamento de Ciencias Farmac\u00e9uticas, Facultad de Ciencias Qu\u00edmicas, Universidad Nacional de C\u00f3rdoba (UNC), C\u00f3rdoba X5000GYA, Argentina"},{"name":"Unidad de Investigaci\u00f3n y Desarrollo en Tecnolog\u00eda Farmac\u00e9utica (UNITEFA), Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET-UNC), Haya de la Torre y Medina Allende, Ciudad Universitaria, C\u00f3rdoba X5000HUA, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic Fibrosis: A Review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1542\/pir.2019-0212","article-title":"Cystic fibrosis","volume":"42","author":"Collaco","year":"2021","journal-title":"Pediatr. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/piac052","article-title":"Opportunistic Pathogens in Cystic Fibrosis: Epidemiology and Pathogenesis of Lung Infection","volume":"11","author":"Blanchard","year":"2022","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/ppul.25353","article-title":"State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonay exacerbations: III. Executive summary","volume":"56","author":"Epps","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"ref_5","unstructured":"McDermott, G., Reece, E., and Renwick, J. (2019). Encyclopedia of Microbiology, Academic Press."},{"key":"ref_6","first-page":"60","article-title":"Updated Treatment of Cystic Fibrosis","volume":"28","author":"Fielbaum","year":"2017","journal-title":"Rev. Medica Clin. Las Condes"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"121318","DOI":"10.1016\/j.ijpharm.2021.121318","article-title":"Respirable spray dried vancomycin coated magnetic nanoparticles for localized lung delivery","volume":"611","author":"Abdelaziz","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/ppul.26077","article-title":"Pharmacokinetics of intermittent dosed intravenous vancomycin in adult persons with cystic fibrosis","volume":"57","author":"Lindley","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01776-19","article-title":"Phase I, dose-escalating study of the safety and pharmacokinetics of inhaled dry-powder vancomycin (AeroVAnc) in volunteers and patients with cystic fibrosis: A New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus","volume":"64","author":"Waterer","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/ppul.24511","article-title":"Off-label use of intravenous antimicrobials for inhalation in patients with cystic fibrosis","volume":"54","author":"McKinzie","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpharm.2017.09.024","article-title":"Development of fine solid-crystal suspension with enhanced solubility, stability, and aerosolization performance for dry powder inhalation","volume":"533","author":"Lin","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ejps.2013.04.023","article-title":"Equilibrium and release properties of hyaluronic acid-drug complexes","volume":"49","author":"Battistini","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jddst.2015.09.014","article-title":"Self-organized drug-interpolyelectrolyte nanocomplexes loaded with anionic drugs. Characterization and in vitro release evaluation","volume":"30","author":"Palena","year":"2015","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/10610270903469757","article-title":"Comparative study of three structurally related acid polyelectrolytes as carriers of basic drugs: Carbomer, Eudragit L-100 and S-100","volume":"22","author":"Ardusso","year":"2010","journal-title":"Supramol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1179\/joc.2010.22.5.328","article-title":"Enhanced bacterial uptake and bactericidal properties of ofloxacin loaded on bioadhesive hydrogels against Pseudomonas aeruginosa","volume":"22","author":"Romero","year":"2010","journal-title":"J. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejps.2014.09.008","article-title":"Hyaluronan as drug carrier. the in vitro efficacy and selectivity of Hyaluronan-Doxorubicin complexes to affect the viability of overexpressing CD44 receptor cells","volume":"65","author":"Battistini","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12931-016-0442-4","article-title":"Effects of inhaled high-molecular weight hyaluronan in inflammatory airway disease","volume":"17","author":"Lamas","year":"2016","journal-title":"Respir. Res."},{"key":"ref_18","first-page":"78","article-title":"Hyaluronic Acid in Inflammation and Tissue Regeneration","volume":"28","author":"Litwiniuk","year":"2016","journal-title":"Wounds"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"M\u00e1iz Carro, L., and Mart\u00ednez-Garc\u00eda, M.A. (2020). Use of Hyaluronic Acid (HA) in Chronic Airway Diseases. Cells, 9.","DOI":"10.3390\/cells9102210"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/ppul.24901","article-title":"Hyaluronic acid for the treatment of airway diseases in children: Little evidence for few indications","volume":"55","author":"Peroni","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"ref_21","unstructured":"United State Pharmacopeia and National Formulary (USP-NF30) (2012). <616>, Bulk Density and Tapped Density of Powders, The United States Pharmacopeial Convention."},{"key":"ref_22","unstructured":"United State Pharmacopeia and National Formulary (USP-NF) (2012). <1174> Powder Flow, The United States Pharmacopeial Convention."},{"key":"ref_23","unstructured":"United State Pharmacopeia and National Formulary (USP-NF) (2012). <601>. Aerosols, Metered-Dose Inhalers and Dry Powder Inhalers, The United States Pharmacopeial Convention."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0376-7388(00)80471-8","article-title":"Modelling of drug diffusion through swellable polymeric systems","volume":"7","author":"Peppas","year":"1980","journal-title":"J. Memb. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e01864-19","DOI":"10.1128\/JCM.01864-19","article-title":"The clinical and laboratory standards institute subcommittee on Antimicrobial susceptibility testing: Background, organization, functions, and processes","volume":"58","author":"Weinstein","year":"2020","journal-title":"J. Clim. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12010-016-2326-y","article-title":"Improvement Production of Hyaluronic Acid by Streptococcus zooepidemicus in Sugarcane Molasses","volume":"182","author":"Pan","year":"2017","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9434","DOI":"10.1007\/s10853-021-05828-y","article-title":"One-pot synthesis of vancomycin-encapsulated ZIF-8 nanoparticles as multivalent and photocatalytic antibacterial agents for selective-killing of pathogenic gram-positive bacteria","volume":"56","author":"Hao","year":"2021","journal-title":"J. Mater. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1021\/acs.molpharmaceut.5b00062","article-title":"Pulmonary Delivery of Vancomycin Dry Powder Aerosol to Intubated Rabbits","volume":"12","author":"Sullivan","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.msec.2014.01.052","article-title":"Chemical functionalization of hyaluronic acid for drug delivery applications","volume":"38","author":"Vasi","year":"2014","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_30","unstructured":"Andronescu, E., and Grumezescu, G.M. (2017). Micro and Nanotechnologies, Elsevier Inc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2016.01.002","article-title":"Amorphous powders for inhalation drug delivery","volume":"100","author":"Chen","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1021\/acs.molpharmaceut.6b00905","article-title":"Inhalation of Respirable Crystalline Rifapentine Particles Induces Pulmonary Inflammation","volume":"14","author":"Parumasivam","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_33","first-page":"251","article-title":"New Inhaled Antibiotics and Forms of Administration","volume":"2","author":"Carro","year":"2020","journal-title":"Open Respir. Arch."},{"key":"ref_34","unstructured":"Andronescu, E., and Grumezescu, G.M. (2017). Micro and Nanotechnologies, Elsevier Inc."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Chaurasiya, B., and Zhao, Y.Y. (2021). Dry powder for pulmonary delivery: A comprehensive review. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13010031"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.apsb.2016.03.011","article-title":"Influence of physical properties of carrier on the performance of dry powder inhalers","volume":"6","author":"Peng","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijpharm.2016.12.002","article-title":"Engineered sodium hyaluronate respirable dry powders for pulmonary drug delivery","volume":"517","author":"Martinelli","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1016\/j.xphs.2020.05.027","article-title":"Development of a Carrier-Free Dry Powder Ofloxacin Formulation With Enhanced Aerosolization Properties","volume":"103","author":"Ceschan","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1080\/03639045.2019.1652636","article-title":"Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: Optimization of powder construction","volume":"45","author":"Altay","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/A:1014426530935","article-title":"Fundamental effects of particle morphology on lung delivery: Predictions of Stokes\u2019 law and the particular relevance to dry powder inhaler formulation and development","volume":"19","author":"Crowder","year":"2002","journal-title":"Pharm. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.apt.2013.09.012","article-title":"Formation of particles for dry powder inhalers","volume":"25","author":"Gradon","year":"2014","journal-title":"Adv. Powder Technol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/jps.20943","article-title":"Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics","volume":"96","author":"Papadopoulos","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1208\/s12249-009-9313-3","article-title":"Effect of particle shape on dry particle inhalation: Study of flowability, aerosolization, and deposition properties","volume":"10","author":"Hassan","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/187221107779814159","article-title":"Development of Dry Powder Inhalers","volume":"1","author":"Chougule","year":"2008","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"ref_45","first-page":"125","article-title":"Vigna mungo mucilage\u2014A natural polymer in the design of matrix based SR tablet of aceclofenac","volume":"21","author":"Basavaraj","year":"2013","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"103958","DOI":"10.1016\/j.jddst.2022.103958","article-title":"A novel particle engineering method for the production of inhalable cromolyn sodium powders by a combination of spray drier and nebulizer","volume":"78","author":"Hamedani","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s11095-008-9538-y","article-title":"The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations","volume":"25","author":"Shur","year":"2008","journal-title":"Pharm. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ijpharm.2016.06.032","article-title":"Preparation of theophylline inhalable microcomposite particles by wet milling and spray drying: The influence of mannitol as a co-milling agent","volume":"514","author":"Malamatari","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/jps.23525","article-title":"New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients","volume":"102","author":"Amighi","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejpb.2016.07.012","article-title":"Reduced food interaction and enhanced gastrointestinal tolerability of a new system based on risedronate complexed with Eudragit E100: Mechanistic approaches from in vitro and in vivo studies","volume":"107","author":"Guzman","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_51","unstructured":"(2022, May 10). Vancomycin Monograph in \u201cDrugBank Online\u201d. Available online: https:\/\/go.drugbank.com\/drugs\/DB00512."},{"key":"ref_52","unstructured":"Bruschi, M.L. (2015). Strategies to Modify the Drug Release from Pharmaceutical, Elsevier. [1st ed.]."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1086\/346207","article-title":"Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997\u20132001","volume":"36","author":"Fridkin","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","first-page":"373","article-title":"\u00bfImpacto de la concentraci\u00f3n m\u00ednima inhibitoria de vancomicina o incorrecto manejo terap\u00e9utico en el fracaso cl\u00ednico por Staphylococcus aureus resistentes a meticilina?","volume":"85","author":"Canal","year":"2015","journal-title":"Ann. Peidatria"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/4\/436\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:17:49Z","timestamp":1760105869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/4\/436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":54,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["pharmaceutics16040436"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16040436","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,22]]}}}